While rare, solid malignancies with BRAF fusion may be targeted by MEK inhibitors, based on a study evaluating trametinib in melanoma with non-V600E BRAF mutation or BRAF fusion, although additional study in other solid malignancies is needed [23]. Here, MAP2K7 is linked to melanoma.